CRL Charles River Laboratories
$314.32 -4.15%
US Stock · Health Care
RSI (14) · 30 / 70 bands
MACD (12, 26, 9)
Solid = close · dashed = 50-day MA · bars = volume. Toggle Bollinger / RSI / MACD. Point at or drag across the chart to read a day. EOD data.
1D
-4.15%
YTD
+57.60%
P/E
375.16
P/B
3.16
ROE
1.3%
Div yield
—
Beta
1.25
Market cap
$15.1B
RSI (14)
43
Next earnings
Feb 16, 2027
Same sector · Health Care
Compare CRL with NVO and JNJ →Follow CRL in the AlfaCat app
Watchlist, price and earnings alerts, the chart offline. Free, no account, no ads.
The economy behind it · United States
Economy this week on BullDozer →GDP, % on year
2.1
Q3 2026
Inflation, %
3.7
Sep 2026
Unemployment, %
3.9
Oct 2026
10-yr yield, %
5.13
Oct 2026
From BullDozer, our sister site for country statistics (open sources: OECD, IMF, Eurostat, ILO). Full United States profile →
Previous session
close of Nov 20, 2026 · EOD, no live order bookOpen
$324.98
Close
$314.32
Day high
$327.23
Day low
$310.52
Volume
1.2M
Latest headlines
Charles River Stock Surges 102.3% in a Year: What's Fueling the Drive?
Yahoo Finance · Nov 20
Oncology Based in-Vivo CRO - Global Strategic Business Report 2026: Capitalize on the $1.7 Billion 2032 Market with Charles River, Crown Bioscience, Wuxi AppTec and Eurofins
Yahoo Finance · Nov 20
Global Preclinical CRO Services Market Opportunities and Strategies to 2035 | Capitalize on AI, Oncology and Biomarkers with Charles River, WuXi AppTec, Eurofins and Pharmaron
Yahoo Finance · Nov 18
Charles River Laboratories International (CRL) Recovers Following Cyclical Contraction
Yahoo Finance · Nov 18
Should You Continue to Hold Charles River Stock in Your Portfolio?
Yahoo Finance · Nov 18
Charles River Laboratories International (CRL) Opens Dublin Site and South Korea Depot
Yahoo Finance · Nov 17
Headlines via Yahoo Finance · links open the source · not an endorsement.
Recent SEC filings
8-K Nov 9, 2026 View → 10-Q Nov 4, 2026 View → 8-K Nov 4, 2026 View → 8-K Sep 24, 2026 View → 10-Q Aug 5, 2026 View →
Source: SEC EDGAR · opens the official filing.
Research & reports
External resources — availability and opinions are theirs, not ours.
This is reference data for your own analysis — not a recommendation to buy or sell CRL. Try it in the Lab to size a position and see the risk.